Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase
PALM BEACH, Fla. June 17, 2024 - According to a report from Mordor Intelligence, the Acute Myeloid Leukemia (AML) market is projected to reach a size of USD 2.97 billion by 2029, growing at a CAGR of 10.15% during the forecast period (2024-2029). This market is estimated to be worth USD 1.83 billion in 2024. The report highlights several key factors contributing to this growth, including the high incidence and prevalence of AML, advances in pharmacology and molecular biology, and increased investments in research and development by pharmaceutical companies.
AML is a type of cancer characterized by the rapid growth of abnormal white blood cells in the bone marrow. According to the American Cancer Society, there will be an estimated 60,650 new cases of leukemia in the US in 2022, with 20,050 of them being AML cases. These statistics are driving the adoption of AML therapies, particularly in developed countries like the US.
One of the main drivers of the AML market’s growth is the increasing investment in research and development. Pharmaceutical companies are conducting a greater number of clinical trials to demonstrate the effectiveness of their drugs. These trials aim to improve the understanding of AML and develop more targeted and efficient treatments. As a result, the market is expected to expand steadily over the forecast period.
Several biotech and pharma companies are actively participating in this market. Companies such as Actinium Pharmaceuticals, Inc. Bio-Path Holdings, Inc. Longeveron, SELLAS Life Sciences Group, Inc. and Bristol Myers Squibb are at the forefront of developing innovative therapies for AML. Their contributions are playing a vital role in advancing the treatment options available to patients.
The growth of the AML market is a positive development for patients and healthcare providers. It signifies the progress being made in understanding and combating this deadly disease. With increased investments, clinical trials, and advancements in pharmacology and molecular biology, the future for AML patients looks promising.
In conclusion, the Acute Myeloid Leukemia market is expected to reach USD 2.97 billion by 2029, driven by factors such as high incidence and prevalence, advancements in pharmacology and molecular biology, and increased investments in research and development. As the understanding of AML improves and more effective treatments are developed, the prognosis for patients is likely to improve significantly.
Comments